{"filings":[{"id":1473917,"accession_number":"0001193125-26-296398","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2026-07-06T21:15:46+00:00","items":["2.03","1.01","8.01","9.01"],"status":"ready","headline":"Nuvation Bio completes full greenshoe, raising $287.5M in convertible notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Underwriters exercised full over-allotment for additional $37.5M of 0.75% Convertible Senior Notes due 2032.","Total aggregate principal amount of Notes sold: $287.5M; estimated net proceeds ~$277.6M.","Net proceeds used to pay $2.2M for additional capped call transactions; remainder for general corporate purposes.","Capped call transactions have cap price of $10.4580 per share, an 80% premium over June 25 closing price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1362876,"accession_number":"0001193125-26-290823","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2026-06-30T21:17:05+00:00","items":["1.01","8.01","1.02","2.03","9.01"],"status":"ready","headline":"Nuvation Bio closes $250M 0.75% convertible senior notes offering due 2032","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$250M aggregate principal of 0.75% Convertible Senior Notes due 2032; initial conversion price ~$7.84/share (35% premium).","Net proceeds ~$241.2M; used to repay $58.5M loan, pay $14.9M for capped call, remainder for general corporate.","Capped call transactions entered to reduce dilution; cap price $10.4580/share (80% premium).","Underwriters' 30-day option for additional $37.5M notes.","Prior loan agreement terminated upon full repayment of ~$58.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":695916,"accession_number":"0001193125-26-241922","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2026-05-27T20:16:22+00:00","items":["5.07"],"status":"ready","headline":"Nuvation Bio stockholders elect directors, ratify KPMG, approve say-on-pay at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class A directors Robert B. Bazemore Jr. and Robert Mashal elected with 197.7M and 216.8M votes for, respectively.","Class B director Kim Blickenstaff elected with 1,000,000 votes for (no withhold).","Ratification of KPMG as independent auditor for FY 2026 approved with 290.3M votes for.","Advisory say-on-pay resolution passed with 230.1M votes for, 5.0M against, and 55.6M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95665,"accession_number":"0001193125-26-204056","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio Q1 2026 net product revenue $18.5M; net income $5.4M vs loss year ago","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $18.5M from IBTROZI; net income $5.4M ($0.02 basic EPS) vs net loss $53.2M year ago.","Collaboration revenue $64.7M including $58.7M upfront from Eisai; cash and securities $533.7M.","Over 600 patients started IBTROZI since launch; majority of ~200 new Q1 patients were TKI-naïve.","Acquired Japan rights to safusidenib from Daiichi Sankyo, gaining full global development and commercialization rights.","Updated pooled TRUST data at AACR: mPFS 46.1 months, mDOR 49.7 months in TKI-naïve ROS1+ NSCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":83228000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108889,"accession_number":"0001193125-26-085474","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio Reports Q4 2025 Revenue of $15.7M, 216 New IBTROZI Patient Starts","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["IBTROZI (taletrectinib) launched in June 2025; 432 new patient starts by end of Q4 2025, with 216 in Q4 alone.","Entered exclusive licensing/collaboration with Eisai on Jan 11, 2026 for taletrectinib in Europe and other regions.","Cash, equivalents, and marketable securities of $529.2M as of Dec 31, 2025.","Net product revenue from IBTROZI: $15.7M in Q4 2025, $24.7M for full year 2025.","Positive Phase 2 safusidenib results published; ORR 44%, 88% progression-free at 24 months in grade 2 IDH1-mutant glioma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108888,"accession_number":"0001193125-26-009826","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"Nuvation Bio licenses taletrectinib to Eisai for up to €195M; Q4 IBTROZI rev $15.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive license to Eisai for taletrectinib in EU, Canada, Australia, Middle East, India, others; upfront €50M, up to €145M milestones, royalties up to high-teens.","Preliminary Q4 IBTROZI net revenue $15.7M; total $24.7M since June 2025 launch; 432 new patient starts.","Preliminary cash $529.2M at Dec 31, 2025; received $25M milestone from Nippon Kayaku.","MAA for taletrectinib in Europe expected H1 2026; first €25M milestone upon EU approval.","Company continues enrollment of safusidenib phase 3 study in IDH1-mutant gliomas; full FY2025 results due March 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125347,"accession_number":"0001193125-25-298551","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Nuvation Bio discontinues NUV-1511 DDC program; redirects $100-150M to pipeline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinued NUV-1511 due to inconsistent efficacy across cohorts; DDC platform continues.","Projected $100-150M in R&D/CMC costs through 2029 reallocated to other pipeline molecules.","First patient enrolled in part 2 of G203 study of safusidenib for IDH1-mutant glioma.","Continued investment in IBTROZI (taletrectinib) commercial launch and TRUST-IV adjuvant study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125346,"accession_number":"0001193125-25-284845","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Nuvation Bio reports Phase 2 ORR 44.4% for safusidenib in IDH1-mutant gliomas","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Safusidenib met primary endpoint with 44.4% objective response rate in 27 Japanese patients with grade 2 IDH1-mutant gliomas.","Median PFS not reached at median 28 months follow-up; 87.9% progression-free at 24 months.","Grade 3+ treatment-related adverse events in 18.5% of patients; no grade 5 events; GCP noncompliance on safety reporting resolved via re-collection.","Company progressing G203 global Phase 3 study for high-risk IDH1-mutant glioma; FDA agreed PFS by BICR per RANO 2.0 could support full approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125345,"accession_number":"0001193125-25-262576","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio Q3 net loss widens to $55.8M; first IBTROZI revenue $7.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $55.8M ($0.16 loss per share) vs. $41.2M ($0.15) in Q3 2024.","Net product revenue from IBTROZI $7.7M; collaboration revenue $5.4M (up from $0.7M).","204 new patients started IBTROZI in Q3; median duration of response matured to 50 months.","Cash, cash equivalents, and marketable securities $549.0M at Sept 30, 2025.","First patients enrolled in TRUST-IV adjuvant study and safusidenib G203 study."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":21037000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142060,"accession_number":"0001193125-25-174954","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio Q2 net loss $59M; IBTROZI launch with 70 patients in 7 weeks","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA approved IBTROZI (taletrectinib) for ROS1+ NSCLC on June 11; 70 patients started by July 31.","Cash, equivalents and marketable securities $607.7M; received $200M non-dilutive financing from Sagard.","Product revenue net $1.2M from IBTROZI for 13 days of sales; collaboration revenue $3.6M (up from $1.4M).","Net loss $59M ($0.17/sh) vs $462.5M ($1.89) in prior year which included AnHeart acquisition cost.","NCCN guidelines added taletrectinib as preferred agent across lines of therapy for ROS1+ NSCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":7917000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160035,"accession_number":"0001193125-25-139164","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Nuvation Bio announces FDA approval of IBTROZI (taletrectinib) for ROS1+ NSCLC","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved IBTROZI for adult patients with locally advanced or metastatic ROS1+ NSCLC.","In TRUST-I, cORR of 90% in TKI-naïve patients; TRUST-II cORR of 85%; median DOR not yet reached.","Intracranial response in 73% of TKI-naïve and 63% of TKI-pretreated patients with brain metastases.","Generally well-tolerated; 7% discontinued due to TEAEs; most common AEs: diarrhea (64%), nausea (47%), vomiting (43%).","Approved dose 600 mg once-daily; half-life ~66 hours enabling sustained CNS exposure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160034,"accession_number":"0001193125-25-125763","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nuvation Bio stockholders elect directors, ratify auditor, approve say-on-pay at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All three proposals passed at May 21, 2025 annual meeting; quorum of 82.8% of Class A shares present.","Kathryn E. Falberg elected Class A director with 198.6M for, 18.0M withheld; David Hung elected Class B director with 1.0M for.","Ratification of KPMG LLP as auditor for FY2025: 279.9M for, 1.6M against, 15.8K abstain.","Advisory approval of named executive officer compensation: 214.9M for, 1.6M against, 143.8K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160033,"accession_number":"0001193125-25-114908","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio Q1 net loss $53.2M; cash $461.7M; taletrectinib PDUFA June 23, 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $53.2M ($0.16/share) vs $14.8M ($0.07) in Q1 2024; R&D rose to $24.6M, SG&A to $35.4M.","Cash, equivalents and marketable securities $461.7M as of March 31, 2025.","FDA Priority Review for taletrectinib NDA on track; PDUFA goal date June 23, 2025.","Secured up to $250M non-dilutive financing from Sagard Healthcare; $150M royalty and $50M debt upon FDA approval.","Appointed Stephen Dang, Ph.D., as Senior Vice President, General Counsel in March 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":3084000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178369,"accession_number":"0001193125-25-062031","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Nuvation Bio enters commercial supply agreement with Asymchem for taletrectinib drug product","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Asymchem will be non-exclusive supplier of taletrectinib drug product; Nuvation retains right to use alternate manufacturers.","Orders must be placed at least 180 days before delivery; cancellation subject to tiered fees.","Initial term is 5 years, auto-renews for consecutive 3-year terms unless non-renewed.","Company may terminate without cause on 30 days' notice; each party may terminate for material breach or insolvency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178368,"accession_number":"0001193125-25-048529","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio: taletrectinib NDA Priority Review, $250M financing, Q4 net loss $49.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA accepted NDA for taletrectinib with Priority Review; PDUFA goal date June 23, 2025 for advanced ROS1+ NSCLC.","Secured up to $250M non-dilutive financings from Sagard: $150M royalty interest plus $50M debt upon FDA approval.","Q4 net loss $49.4M ($0.15/sh) vs $13.8M ($0.06) in Q4 2023; R&D and SG&A rose due to AnHeart acquisition.","China NMPA approved taletrectinib Jan 2025 (Innovent commercializing); Nippon Kayaku submitted MAA in Japan.","Launched U.S. Expanded Access Program for taletrectinib in February 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178367,"accession_number":"0001193125-25-047165","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Nuvation Bio enters 5-year supply agreement with Asymchem for taletrectinib drug substance","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Asymchem will be a non-exclusive supplier; Nuvation retains right to use alternate manufacturers.","Initial term of 5 years, auto-renews for 3-year periods unless either party gives 6-month nonrenewal notice.","Orders must be placed at least 180 days before delivery; cancellations incur tiered percentage fees.","Company may terminate without cause on 30 days' notice; either party may terminate for material breach or insolvency.","Agreement covers delivery, quality, IP, confidentiality, and indemnification; financial terms not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178366,"accession_number":"0001193125-25-045568","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Nuvation Bio secures up to $250M in debt and royalty financing for taletrectinib","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$100M loan with Sagard; initial $50M tranche upon FDA approval of taletrectinib by Sep 30, 2025; second $50M upon first US commercial sale by Jun 30, 2026","Loan matures Sep 30, 2030, interest SOFR (4% floor) + 6% quarterly; prepayment premiums; $25M minimum cash covenant","$150M revenue interest financing; tiered royalties: 5.5% on US net sales up to $600M, 3.0% on $600M-$1B, none above $1B","Royalty obligation ends at 1.6x-2.0x investment amount; true-up if not repaid by Feb 1, 2043","Company can buy out royalty at 140%-200% of investment amount less payments made; investor can put upon certain events"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178365,"accession_number":"0001193125-25-025099","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Dr. Jerry Wang exits AnHeart Therapeutics CEO role after taletrectinib milestones achieved","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Wang departed as CEO of AnHeart Therapeutics, a Nuvation Bio subsidiary, on Feb. 12, 2025.","Departure follows China NMPA approval of taletrectinib for advanced ROS1-positive NSCLC.","Also follows FDA acceptance and priority review of NDA for taletrectinib in advanced ROS1-positive NSCLC.","Dr. Wang resigned from Nuvation Bio board effective Feb. 11, 2025; no disagreement with company.","Role eliminated as redundant after successful integration of AnHeart Therapeutics post-merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195020,"accession_number":"0001193125-24-252153","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio reports Q3 net loss of $41.2M, submits NDA for taletrectinib in ROS1+ NSCLC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $41.2M ($0.15 per share) vs $19.6M ($0.09) in Q3 2023; cash of $549.1M at Sept 30.","NDA for taletrectinib submitted to FDA for line-agnostic full approval in advanced ROS1+ NSCLC; potential launch mid-2025.","Pooled Phase 2 data: 89% ORR in TKI-naïve patients, median DOR 44 months and PFS 46 months; low 7% discontinuation rate.","Appointed Philippe Sauvage as CFO in October; David Hung appointed Chairman, Robert Bazemore lead independent director.","R&D expenses $27.7M (up $9.2M YoY); G&A $19.6M (up $11.8M YoY) driven by AnHeart acquisition costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":2162000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195019,"accession_number":"0001193125-24-233794","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nuvation Bio appoints Philippe Sauvage as CFO effective October 7, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Philippe Sauvage appointed CFO; previously SVP Global Head of Operations & Access at Sanofi (2020-2024).","Initial annual base salary of $510,000; annual discretionary bonus up to 45% of base.","Option award for 750,000 shares; vests 1/4 on one-year anniversary, then monthly vesting.","Severance: 12 months base salary plus COBRA reimbursement; change-in-control double trigger with full equity acceleration.","No family relationships or material transactions with directors or officers disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211310,"accession_number":"0001193125-24-214241","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Nuvation Bio shareholders approve 85M share conversion; CEO Hung named Board Chair","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved conversion of Series A Preferred into up to 85,120,200 Class A shares; conversion completed Sept 4, resulting in 333.8M Class A shares outstanding.","CEO David Hung appointed Chair of the Board; Robert Bazemore appointed Lead Independent Director.","Committee chairs set: Falberg (Audit), Vernon (Compensation), Bazemore (Nominating/Governance).","All five proposals passed: directors elected, KPMG ratified, executive compensation approved, conversion approved, adjournment approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211309,"accession_number":"0001193125-24-193412","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio Q2 net loss $462.5M on $425.1M AnHeart charge; halts NUV-868 Phase 2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $462.5M ($1.89/share) vs. $20.6M ($0.09) Q2 2023; includes $425.1M acquired IPR&D charge from AnHeart acquisition.","Cash, equivalents, and marketable securities of $577.2M as of June 30, 2024.","R&D expenses $29.2M (up 57% YoY) and G&A $16.1M (up 115% YoY) partly due to AnHeart.","Decided not to initiate Phase 2 for NUV-868 in prior solid tumor indications; evaluating next steps.","Taletrectinib NDA planned in U.S. in 2025 based on pooled TRUST-I/II data at ESMO 2024; received FDA Orphan Drug Designation."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":1435000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229878,"accession_number":"0001193125-24-164595","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K/A","filed_at":"2024-06-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nuvation Bio files 8-K/A with AnHeart financials and updated taletrectinib clinical data","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Acquired AnHeart in Apr 2024; audited AnHeart FY2023 and FY2022 financials included.","Taletrectinib TRUST-I: 90.6% cORR in TKI-naive ROS1+ NSCLC; median PFS not reached at 23.5 mo f/u.","Intracranial cORR 87.5% (TKI-naive) and 73.3% (TKI-pretreated) in TRUST-I; low neuro TEAEs.","NDA accepted in China with priority review for taletrectinib; Breakthrough Therapy in US and China.","Innovent out-license: $55M received; up to $29M regulatory + $105M commercial milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229880,"accession_number":"0001193125-24-138263","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio Q1 net loss $14.8M; completes AnHeart acquisition; cash $597M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.8M ($0.07 per share) vs $21.7M ($0.10) in Q1 2023.","Cash, equivalents and marketable securities of $597.0M as of March 31, 2024.","Acquisition of AnHeart Therapeutics closed in April 2024, transforming Nuvation into late-stage global oncology company.","Appointed Colleen Sjogren as Chief Commercial Officer; first patient dosed in Phase 1/2 study of NUV-1511 DDC.","Updated taletrectinib Phase 2 TRUST-I data to be presented at ASCO 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229879,"accession_number":"0001193125-24-091875","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2024-04-10T23:59:59+00:00","items":["1.01","2.01","3.02","3.03","5.03","5.02","9.01"],"status":"ready","headline":"Nuvation Bio completes acquisition of AnHeart Therapeutics; issues ~27.6M shares and ~85M potential convertible shares","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Completed acquisition of AnHeart Therapeutics on April 9, 2024. Issued ~27.6M Class A shares, 851K Series A Convertible Preferred (convertible into ~85.1M shares), and ~2.9M warrants.","Assumed AnHeart options and RSUs covering ~15.9M Class A shares; AnHeart shareholders own ~1/3 of combined company on fully diluted basis.","Appointed Dr. Junyuan (Jerry) Wang (former AnHeart CEO) and Dr. Xiangmin (Min) Cui (Decheng Capital) to the board.","Filed Certificate of Designation for Series A Non-Voting Convertible Preferred; conversion requires stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248356,"accession_number":"0001193125-24-075908","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Nuvation Bio to acquire AnHeart Therapeutics in all-stock merger; AnHeart holders to own ~33%","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Nuvation Bio to acquire AnHeart via merger; will issue ~128.7M shares of Class A common stock and ~2.9M warrants to AnHeart securityholders.","AnHeart shareholders will own about one-third of combined company on fully-diluted basis; Nuvation Bio shareholders retain two-thirds.","Board expands from seven to nine; Junyuan Jerry Wang (Ph.D.) and Xiangmin Cui (Ph.D.) appointed as new directors.","Voting agreements: holders of ~90% of AnHeart shares and Nuvation Bio CEO David Hung (~27% of Nuvation shares) commit to support deal.","Lock-up for 90% of AnHeart shareholders restricts transfer of up to 20% of shares until December 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248355,"accession_number":"0001193125-24-053575","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio Q4 net loss $13.8M ($0.06/shr); cash $611.2M; pipeline advances for NUV-868 and NUV-1511","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $13.8M ($0.06/shr); full-year net loss $75.8M, improved from $104.2M in 2022.","Cash, equivalents and marketable securities $611.2M at Dec 31, 2023.","Completed NUV-868 Phase 1 monotherapy, determined MTD; Phase 1b combo studies (olaparib/enzalutamide) ongoing.","FDA cleared IND for NUV-1511, first DDC candidate; Phase 1/2 study expected to start H1 2024.","Appointed Dr. Robert Mashal to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248354,"accession_number":"0001193125-24-004426","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nuvation Bio appoints Robert Mashal, M.D. to board as Class II director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Mashal appointed to fill vacant board seat effective Jan. 8, 2024; term expires at 2026 annual meeting.","He is a former global head of strategy for immunology/oncology at Sanofi and a board-certified medical oncologist.","Received initial option grant of $770,000 in Class A common stock vesting monthly over three years.","Also eligible for annual cash retainer of $40,000; no committee assignment as of filing date.","Board determined Dr. Mashal qualifies as independent under NYSE listing rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265846,"accession_number":"0001193125-23-295446","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Nuvation Bio director Oleg Nodelman resigns from board effective December 11, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Oleg Nodelman resigned as a member of the Board on December 11, 2023; resignation effective immediately.","Nodelman was not a member of any Board committees.","Resignation not due to any disagreement with the Company or its operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265845,"accession_number":"0001193125-23-283346","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2023-11-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nuvation Bio appoints Moses Makunje as Principal Accounting Officer and Principal Financial Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective Nov 27, 2023; Makunje previously VP Finance since Jan 2022.","Annual base salary of $343,873; eligible for discretionary incentive bonus with 35% target.","CPA with over 16 years experience including at Ernst & Young and Maze Therapeutics.","No family relationships with directors or other officers; no material transactions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265844,"accession_number":"0001193125-23-276021","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nuvation Bio CFO Jennifer Fox resigns effective Nov 27","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Jennifer Fox resigns to pursue a new opportunity; not due to any disagreement with the Company.","Resignation effective November 27, 2023; no replacement named at this time.","Executive management and finance team will assume CFO duties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265843,"accession_number":"0001193125-23-269399","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio Q3 net loss $19.6M ($0.09/shr), cash $619.3M; DDC IND on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $19.6M from $27.2M YoY; loss per share $0.09 vs $0.12.","Cash, equivalents and marketable securities totaled $619.3M as of Sept 30, 2023.","R&D expenses fell to $18.6M from $21.3M, driven by NUV-422 termination and headcount reduction.","Phase 1 monotherapy and Phase 1b combo studies of NUV-868 (BETi) ongoing in advanced solid tumors.","IND submission for first Drug-Drug Conjugate candidate expected by year-end 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283063,"accession_number":"0001193125-23-202881","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio Q2 net loss narrows to $20.6M; cash $630.9M; NUV-868 studies enrolling","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $20.6M ($0.09/share) vs $34.9M ($0.16/share) in Q2 2022.","Cash, cash equivalents and marketable securities of $630.9M as of June 30, 2023.","R&D expenses decreased to $18.6M from $28.9M, partly due to NUV-422 program termination.","Phase 1b combo study of NUV-868 with olaparib/enzalutamide and Phase 1 monotherapy enrolling.","Expects to submit IND for first DDC candidate by year end 2023; formed Scientific Advisory Board."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302452,"accession_number":"0001193125-23-146073","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nuvation Bio annual meeting: directors elected, KPMG ratified, 20% opposed exec pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Director Robert B. Bazemore Jr. re-elected with 140.6M for, 50.1M withheld (26% of votes cast).","Kim Blickenstaff re-elected as Class B director with 1M for, none withheld.","KPMG LLP ratified as auditor for FY2023 with 206.3M for, 0.1M against, 0.3M abstain.","Advisory vote on executive compensation passed 153.7M for, 38.0M against (20% disapproval).","Total shares represented 94% of Class A and 100% of Class B common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302451,"accession_number":"0001193125-23-135935","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio Q1 2023 net loss $21.7M; cash $646.6M; DDC IND on track for year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $21.7M ($0.10 per share) vs $21.3M ($0.10) in Q1 2022.","Cash, cash equivalents and marketable securities of $646.6M as of March 31, 2023.","R&D expenses decreased to $18.8M from $20.7M, primarily due to headcount reduction and NUV-422 program termination.","Phase 1b combo study of NUV-868 with olaparib/enzalutamide and Phase 1 monotherapy study both enrolling.","IND submission for first Drug-Drug Conjugate candidate expected by year-end 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322104,"accession_number":"0001193125-23-071350","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2023-03-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio reports Q4 2022 net loss $20.8M, cash $661M; advances NUV-868 and DDC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2022 $20.8M ($0.10/sh) vs $25.1M ($0.12/sh) Q4 2021; full-year net loss $104.2M.","Cash, equivalents and marketable securities $661.0M as of Dec 31, 2022; no debt disclosed.","R&D expense Q4 2022 $16.9M (down from $22.0M); G&A $7.4M (vs $7.6M) YoY.","Dosed first patient in Phase 1b combo study of NUV-868 with olaparib or enzalutamide; Phase 1 monotherapy ongoing.","Nominated first DDC clinical candidate; expects IND submission by end of 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322103,"accession_number":"0001193125-23-058263","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2023-03-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nuvation Bio files Delaware court petition to validate share increase amendments after Boxed ruling","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed petition in Delaware Court of Chancery under Section 205 of DGCL to validate charter amendment increasing authorized shares of Class A from 500M to 1B and Class B from 20M to 60M.","Petition follows December 2022 Boxed ruling that created uncertainty about whether separate class votes were required for share increases by SPACs.","Hearing set for March 14, 2023; company warns failure to validate could materially impact ability to timely file 2022 Form 10-K.","Company states that majority of all common stock voted in favor, and that Class A holders actually provided majority support even without separate vote.","If validation is not granted, uncertainty could affect validity of shares issued since February 2021 and ongoing operational matters like ESPP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340194,"accession_number":"0001193125-22-311807","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2022-12-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nuvation Bio updates slide deck with clinical development timeline and milestones","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed under Regulation FD; presentation available on company website.","Updated clinical timeline and milestones shared for pipeline candidates.","No specific financial or trial data disclosed in the 8-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340193,"accession_number":"0001193125-22-276899","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio Q3 net loss $27.2M; cash $673.9M; NUV-868 Phase 1b on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $27.2M ($0.12/share) vs $22.0M ($0.11/share) in Q3 2021.","Cash, cash equivalents and marketable securities of $673.9M as of Sep 30, 2022; runway through 2028.","R&D expenses $21.3M (incl. $1.6M restructuring and $5.7M contract termination costs).","Phase 1 monotherapy of NUV-868 dosing; Phase 1b combo with olaparib/enzalutamide expected by end of 2022.","DDC platform first clinical candidate nomination on track for end of 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357456,"accession_number":"0001193125-22-212548","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio Q2 net loss $34.9M; restructures with 35% workforce cut","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, marketable securities $703.8M as of June 30, 2022; runway through 2028.","R&D expense $28.9M (up 106% YoY), G&A $8.9M (up 39% YoY) on higher headcount and stock comp.","Phase 1 monotherapy dosing underway for BET inhibitor NUV-868 in advanced solid tumors.","Appointed Dr. David Liu as CMO (July) and Kerry Wentworth as CRO (May) to Executive Committee.","Restructuring announced Aug 1, reducing workforce by 35% to cut costs and align with re-prioritized pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357455,"accession_number":"0001193125-22-207816","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2022-08-01T23:59:59+00:00","items":["2.02","2.05","8.01"],"status":"ready","headline":"Nuvation Bio discontinues NUV-422 program due to uveitis safety; cuts 35% of staff","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinued NUV-422 clinical program after FDA partial clinical hold due to unpredictable uveitis safety signal.","Workforce reduction of ~30 employees (35%) expected to save ~$11.8M annually; restructuring charges of ~$5.8M in Q3 2022.","Cash, cash equivalents and marketable securities of ~$703.8M as of June 30, 2022; cash runway extended through 2028.","Prioritizing NUV-868 (BD2-selective BET inhibitor) and novel small molecule DDC platform for future development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376055,"accession_number":"0001193125-22-153069","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2022-05-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nuvation Bio stockholders elect directors, ratify KPMG, approve 1-year say-on-pay frequency","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors elected: Falberg 175.6M for, Nodelman 146.2M for (Class A); Hung 1.0M for (Class B).","Ratification of KPMG as auditor for FY2022: 204.96M for, 65,540 against, 111,785 abstain.","Advisory vote on executive compensation frequency: 191.88M voted for 1-year; company will adopt that frequency.","94% of Class A and 100% of Class B common stock present; quorum achieved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376054,"accession_number":"0001193125-22-145022","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2022-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio Q1 net loss $21.3M; pipeline focus on NUV-422, NUV-868, DDC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.3M ($0.10 per share) vs $20.4M ($0.12) in Q1 2021.","Cash, cash equivalents and marketable securities $737.7M as of March 31, 2022.","R&D expenses $20.7M (up $4.8M YoY); G&A $7.5M (up $2.9M YoY).","On track to initiate Phase 1b combos and Phase 2 monotherapy for NUV-422 by end-2022; first patient dosed in NUV-868 Phase 1.","Deprioritized early-stage NUV-569 and A2A programs to allocate resources to NUV-422, NUV-868, and DDC program."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394391,"accession_number":"0001193125-22-058273","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2022-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio Q4 net loss $25.1M, cash $765.4M; NUV-422 gets Fast Track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2021 was $25.1M ($0.12/share) vs $13.3M ($0.11) in Q4 2020.","Full-year 2021 net loss $86.8M vs $41.7M in 2020; R&D spend $69.0M (up from $32.6M).","Cash, equivalents, and marketable securities $765.4M as of Dec 31, 2021.","FDA Fast Track for NUV-422 (high-grade gliomas); IND cleared for NUV-868 (solid tumors).","Expects Phase 1 safety data for NUV-422 in 2022; multiple pipeline milestones planned."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394390,"accession_number":"0001193125-22-005788","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Nuvation Bio reports estimated cash of $765M as of Dec. 31, 2021","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Estimated cash, cash equivalents, and marketable securities of $765M as of December 31, 2021.","Announcement made via Form 8-K on January 10, 2022.","No other financial results or forward guidance provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394389,"accession_number":"0001193125-22-004997","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nuvation Bio to present at JPM 2022; no specific financial or pipeline updates disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company conducting investor meetings at 40th Annual J.P. Morgan Healthcare Conference starting Jan 10, 2022.","Slide presentation furnished as Exhibit 99.1 contains only a title slide; no detailed data available.","No earnings, clinical trial results, or guidance changes announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412996,"accession_number":"0001193125-21-325991","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio Q3 2021 net loss $22.0M; cash $791.8M; NUV-422 enrollment ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $22.0M ($0.11 per share) vs $11.0M ($0.12) in Q3 2020.","R&D expenses $17.1M, up from $8.6M; G&A $5.7M, up from $2.9M.","Cash, equivalents and marketable securities $791.8M as of Sept 30, 2021.","Enrollment ongoing in Phase 1/2 study of NUV-422; top-line data expected 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412995,"accession_number":"0001193125-21-311319","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2021-10-28T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Nuvation Bio terminates collaboration agreement with SPARCBIO LLC effective Jan 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Oct 22, 2021, Nuvation notified SPARCBIO LLC of termination effective Jan 21, 2022 without penalty.","The collaboration agreement was originally dated Jan 21, 2019 among Nuvation, RePharmation, and SPARCBIO LLC.","Company stated it no longer requires the services under the collaboration agreement.","No additional costs, penalties, or new agreements were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":431638,"accession_number":"0001193125-21-244709","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2021-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio Q2 net loss $19.3M; cash $806.6M; NUV-422 trial expands","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.3M ($0.09/share) vs $8.6M loss ($0.10) in Q2 2020.","Cash, cash equivalents and marketable securities $806.6M as of June 30.","R&D expenses $14.0M, up from $7.3M, on higher clinical and preclinical costs.","Phase 1/2 of NUV-422 expanded to glioblastoma, breast, and prostate cancers; Phase 1 data expected 2022.","Appointed David C. Hanley as Chief Technical Operations Officer in June 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}